- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FRACTYL HEALTH Aktie jetzt für 0€ handeln | |||||
| 13.01. | FRACTYL HEALTH, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.12.24 | Fractyl Health, Inc.: Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva Smart GLP-1 Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular ... | 2 | GlobeNewswire (USA) | ||
| 09.12.24 | Fractyl Health, Inc.: Fractyl Health to Present New Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) | 1 | GlobeNewswire (USA) | ||
| 12.11.24 | Fractyl Health, Inc.: Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates | 152 | GlobeNewswire (Europe) | REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 Anticipate reporting data from REVEAL-1 open-label cohort beginning in Q4 2024... ► Artikel lesen | |
| 12.11.24 | Fractyl Health reports Q3 resultsa | 2 | Seeking Alpha | ||
| 04.11.24 | Fractyl Health, Inc.: Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek 2024 | 1 | GlobeNewswire (USA) | ||
| 04.11.24 | Fractyl Health, Inc.: Fractyl Health Presented New Analysis from Pooled Data of Revita Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek 2024 | 149 | GlobeNewswire (Europe) | Single Revita procedure led to sustained, clinically meaningful weight loss in majority of patients with Type 2 Diabetes REMAIN-1 weight maintenance pivotal study on-track to report mid-point data... ► Artikel lesen | |
| 29.10.24 | Fractyl Health, Inc.: Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024 | 1 | GlobeNewswire (USA) | ||
| 28.10.24 | Fractyl Health, Inc.: Fractyl Health to Present Compelling Weight Maintenance Data from both Revita and Rejuva Platforms at ObesityWeek 2024 | 1 | GlobeNewswire (USA) | ||
| 24.09.24 | Fractyl Health, Inc.: Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference | 1 | GlobeNewswire (USA) | ||
| 14.09.24 | Fractyl Health president sells over $188k in company stock | 14 | Investing.com | ||
| 03.09.24 | Fractyl Health, Inc.: Fractyl Health to Participate in Upcoming September Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 14.08.24 | Fractyl Health, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| 07.08.24 | Fractyl Health, Inc.: Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 | 1 | GlobeNewswire (USA) | ||
| 30.07.24 | Fractyl Health, Inc.: Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs | 99 | GlobeNewswire (Europe) | Breakthrough Device Designations are granted by the U.S. FDA to expedite review of promising technologies that address high unmet needs and may improve the lives of people with life-threatening or... ► Artikel lesen | |
| 20.05.24 | Fractyl Health, Inc.: Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024 | 206 | GlobeNewswire (Europe) | Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p Data also demonstrated reductions of 36% in total cholesterol and 51% in low density lipoprotein... ► Artikel lesen | |
| 13.05.24 | Fractyl Health, Inc.: Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates | 724 | GlobeNewswire (Europe) | Initiation of Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 based drugs expected in the second half of 2024 Topline data from Revitalize-1 pivotal... ► Artikel lesen | |
| 13.05.24 | Fractyl Health, Inc.: Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) | 131 | GlobeNewswire (Europe) | First 14 participants with at least six months of follow up continue to demonstrate sustained improvements in blood glucose and weight with reduction in T2D medication utilization after a single Revita... ► Artikel lesen | |
| 02.04.24 | Fractyl Health, Inc.: Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes | 137 | GlobeNewswire (Europe) | BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of... ► Artikel lesen | |
| 01.04.24 | Fractyl Health, Inc.: Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | 275 | GlobeNewswire (Europe) | Received IDE approval for the Revita® Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal Revitalize-1... ► Artikel lesen |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 112,80 | +0,18 % | Evotec, Vidac Pharma, BioNTech - Geld verdienen mit dem Kampf gegen Krebs | Nicht erst seitdem König Charles und Prinzessin Kate ihre Krebsleiden öffentlich gemacht haben ist klar, dass die Krankheit jeden treffen kann. Der Markt wächst und schon heute gehen die Umsätze in... ► Artikel lesen | |
| CUREVAC | 3,660 | -0,49 % | CureVac Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| AMGEN | 264,20 | +0,65 % | Nepsis Inc. Boosts Position in Amgen Inc. (NASDAQ:AMGN) | ||
| NOVAVAX | 8,689 | -1,05 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| BIOGEN | 138,70 | -0,43 % | Biogen Inc.: FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease | Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment
Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation zur Erkennung von fortgeschrittenen Adenomen in einer großen Patientenpopulation | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,130 | +0,73 % | Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week | ||
| INTELLIA THERAPEUTICS | 10,735 | +2,63 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,300 | +0,36 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) | -ORLADEYO net revenue expected to be between $515-$535 million in 2025- -Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025- -Company achieved operating profit in... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,360 | -1,73 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research): Buy / Kursziel: USD 8,50 | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 22.11.2024 / 11:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,579 | -1,15 % | What Analysts Are Saying About Pacific Biosciences Stock | ||
| EXELIXIS | 30,310 | -1,75 % | Exelixis Aktie: Fachmeinungen und Analysen | Die Aktie des Onkologieunternehmens Exelixis verzeichnete am 25. Januar 2025 eine moderate Kurssteigerung von 0,29 Prozent auf 30,70 EUR. Diese Entwicklung erfolgt zeitgleich mit einer bedeutsamen Neubewertung... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 111,55 | +0,54 % | Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory | ||
| VAXART | 0,729 | -2,93 % | Vaxart, Inc. - 8-K, Current Report | ||
| EXACT SCIENCES | 51,94 | -2,64 % | Exact Sciences taps into TV dramas for 'tongue-in-cheek' Cologuard campaign |
Das Unternehmen FRACTYL HEALTH INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,030 (+1,46 %) liegt der Kurs bei 2,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FRACTYL HEALTH INC finden Sie auf Wallstreet Online.
